Unternehmen wird geladen
Jazz Pharmaceuticals plc
JAZZ · Nasdaq · ·
240,40 $-3,1 %Schluss 12. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 2. November 2026
Wertentwicklung in der Vergangenheit
- 1W
- +2,4 %
- 1M
- +14,7 %
JAZZ · Nasdaq · ·
240,40 $-3,1 %Schluss 12. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 2. November 2026
Just reported
From Jazz Pharmaceuticals's results release of 2. November 2026; its quarterly report has since been filed.
Actual
1,24B $
+10 % y/y
+2,9 % q/q
Guided
—
No guide given
Actual
-7,48 $
Guided
—
No guide given
Actual
-413,4M $
The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B $A+
EXELExelixis, Inc.17B $A+
HALOHalozyme Therapeutics, Inc.11,5B $A+
TECHBIO-Techne Corp11,4B $A+
TGTXTG Therapeutics, Inc.9,8B $A+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now ADie Umsatzanteile sind Schätzungen für 2025 und keine Zahlen aus einem eingereichten Bericht.
Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.
Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.
Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).
Gebaut aus den eigenen Einreichungen von Jazz Pharmaceuticals plc bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
Jazz sells low-sodium oxybate medicine for narcolepsy and idiopathic hypersomnia, plus epilepsy and cancer drugs to patients through pharmacies and hospitals.
Unternehmensausblick: Umsatz von 4,8B $ bis 4,9B $ für Geschäftsjahr 2026 — 12,8 % mehr als ein Jahr zuvor
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade A
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 41 Quartalen der Notenhistorie von Jazz Pharmaceuticals plc. Die übrigen 39 reichen zurück bis November 2016.
